EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY-NC-ND 4.0

Relationship between the combination of platelet count and neutrophil‐lymphocyte ratio and prognosis of patients with advanced non‐small cell lung cancer treated with immune checkpoint inhibitors plus chemotherapy: A retrospective cohort study

Saeko Kashimura iD, Miki Sato iD, Takahito Inagaki iD, Masaoki Kin, Ryo Manabe, Sojiro Kusumoto, Atsushi Horiike, Takuya Tsunoda, Mari Kogo iD

Thoracic Cancer · 2024

DOI: 10.1111/1759-7714.15437 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Thoracic Cancer, 2024. Verfasst von Saeko Kashimura und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmacotherapeutics, Department of Clinical Pharmacy, Showa University School of Pharmacy, Tokyo, Japan. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neutrophils, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The relationship between the combination of platelet count and neutrophil‐lymphocyte ratio (COP‐NLR) and prognosis in patients with advanced non‐small cell lung cancer (NSCLC) treated with immune checkpoint inhibitor (ICI) combination therapy with chemotherapy remains unclear. Thus, we investigated prognostic factors, including the COP‐NLR, to identify patients who could benefit from the therapeutic efficacy of ICI combination therapy for advanced NSCLC. Furthermore, we evaluated the relationship between the COP‐NLR score during ICI combination therapy and treatment response.

Methods

We conducted a retrospective cohort study of 88 patients with NSCLC who initially received ICI combination therapy. The primary outcome was overall survival (OS). The prognostic factors were extracted using the Cox proportional hazards model. The relationship between COP‐NLR score at 3 weeks after starting ICI combination therapy and a good response (complete response [CR] and partial response [PR]) to treatment was analyzed using the chi‐square test.

Results

The median OS was 15.7 months. In the multivariable analysis, Eastern Cooperative Oncology Group Performance Status (ECOG PS) 2, distant metastatic sites ≥2, and baseline COP‐NLR scores of 1, 2 were extracted as significant poor prognostic factors. The proportion of patients with CR and PR in the 3‐week COP‐NLR score of 0 group was significantly higher than that in scores of 1, 2 group.

Conclusions

Baseline COP‐NLR, ECOG PS, and number of distant metastatic sites were prognostic factors in patients with NSCLC with ICI combination therapy. A lower 3‐week COP‐NLR was associated with a good response to treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsNeutrophilsImmune Checkpoint InhibitorsHumansRetrospective StudiesFemaleMalePrognosisAgedMiddle AgedPlatelet CountLymphocytesAntineoplastic Combined Chemotherapy ProtocolsAged, 80 and overAdult

Stichwörter der Autor:innen

combination of platelet count and neutrophil‐lymphocyte ratioimmune checkpoint inhibitorsnon‐small cell lung cancerprognosistreatment outcome

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Division of Pharmacotherapeutics, Department of Clinical Pharmacy, Showa University School of Pharmacy, Tokyo, Japan.
  • Department of Hospital Pharmaceutics, School of Pharmacy, Showa University, Tokyo, Japan.
  • Department of Pharmacy, Showa University Northern Yokohama Hospital, Kanagawa, Japan.
  • Department of Pharmacy, Showa University Hospital, Tokyo, Japan.
  • Division of Respirology and Allergology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.
  • Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.

ORCID-Profile: Saeko Kashimura, Miki Sato, Takahito Inagaki, Mari Kogo

Zitieren

APA

Kashimura, S., Sato, M., Inagaki, T., Kin, M., Manabe, R., Kusumoto, S., Horiike, A., Tsunoda, T., & Kogo, M. (2024). Relationship between the combination of platelet count and neutrophil‐lymphocyte ratio and prognosis of patients with advanced non‐small cell lung cancer treated with immune checkpoint inhibitors plus chemotherapy: A retrospective cohort study. Thoracic Cancer. https://doi.org/10.1111/1759-7714.15437

Vancouver

Kashimura S, Sato M, Inagaki T, Kin M, Manabe R, Kusumoto S, et al. Relationship between the combination of platelet count and neutrophil‐lymphocyte ratio and prognosis of patients with advanced non‐small cell lung cancer treated with immune checkpoint inhibitors plus chemotherapy: A retrospective cohort study. Thoracic Cancer. 2024. doi:10.1111/1759-7714.15437

BibTeX
@article{Kashimura2024,
  author = {Kashimura, Saeko and Sato, Miki and Inagaki, Takahito and Kin, Masaoki and Manabe, Ryo and Kusumoto, Sojiro and Horiike, Atsushi and Tsunoda, Takuya and Kogo, Mari},
  title = {Relationship between the combination of platelet count and neutrophil‐lymphocyte ratio and prognosis of patients with advanced non‐small cell lung cancer treated with immune checkpoint inhibitors plus chemotherapy: A retrospective cohort study},
  journal = {Thoracic Cancer},
  year = {2024},
  doi = {10.1111/1759-7714.15437}
}
Kostenlos starten →